# Atavistik Bio **Type:** venture **Status:** Draft **Confidence:** Medium **Focus:** allosteric drug discovery, oncology, precision medicine, structural biology, metabolite-protein interactions **Stage:** Private; clinical-stage; ~$299M raised ($120M Series B, December 2025; $40M extension, March 2026) **Location:** Cambridge, MA (HQ); University of Utah spinout (founding science) **Updated:** 2026-06-19 **Needs-reviewed:** 2026-06-19 **Hero:** https://picsum.photos/seed/atavistik-bio-2026/1600/1100 **Pull:** *A proteome-scale map of metabolite-protein allostery — turned into selective small molecules.* **Relates:** cites [Official Website: Atavistik Bio](atavistik-bio-official-website.md) ## Summary Atavistik Bio is a clinical-stage biotechnology company founded in 2021 to discover drugs targeting allosteric sites — regulatory pockets distinct from active sites — using a platform that maps metabolite-protein interactions at proteome scale. The company is headquartered in Cambridge, Massachusetts, but originates as a University of Utah spinout from the Jared Rutter laboratory. Co-founders are Jared Rutter (Professor, U of U Biochemistry, still on faculty) and Ralph DeBerardinis (UT Southwestern). The Rutter lab's MIDAS/AMPS technology — published in *Science* (2023) — provided the first systematic readout suggesting metabolite regulation of proteins is far more widespread than previously appreciated. Atavistik has raised roughly $299M, including a $120M Series B led by Nextech Invest and The Column Group with Lux Capital and Regeneron Ventures participating. ## Impact Many of the best drug targets are allosteric sites nobody knew existed. Allosteric modulation can be more isoform- and mutation-specific than orthosteric inhibition, potentially improving tolerability. The platform thesis is that systematic metabolite-protein screening expands the druggable genome beyond conventional active-site chemistry. The immediate clinical programs center on selective AKT1 and JAK2 modulation. Legacy research highlighted AKT1 E17K — a common driver mutation in breast, uterine, and colorectal cancers — where pan-AKT inhibitors cause significant toxicity. An allosteric inhibitor specific to mutant AKT1 could be dramatically more tolerable. The company's 2026 official website emphasizes ATV-1601 for hereditary hemorrhagic telangiectasia (HHT), with FDA IND clearance and Fast Track designation announced in June 2026 — suggesting active pipeline evolution as programs mature. If the platform translates, it enables exploration of a target class that has been largely inaccessible; if clinical data fail, the science still documents a new map of cellular regulation from Utah-born research. ## What They Are Building Atavistik combines experimental metabolite-protein screening (MIDAS/AMPS), structural biology, medicinal chemistry, and computational methods to turn allosteric hits into drug-like molecules. Public pipeline descriptions include: - **ATV-1601** — oral, allosteric AKT1-selective inhibitor; Phase 1 activity with 2026 regulatory momentum in HHT per the official website, with earlier public focus on AKT1 E17K solid tumors. - **JAK2 V617F program** — mutant-selective allosteric inhibitor for myeloproliferative neoplasms, in discovery or early development. - **Platform** — systematic allosteric site discovery intended to feed a broader pipeline beyond first assets. Converting metabolite-binding signals into molecules that work in patients remains the core unsolved loop — allosteric sites are conformationally dynamic and context-dependent. ## What They Need Now Likely needs include medicinal chemists, structural biologists, biochemists focused on allostery, computational chemists at the ML/structure intersection, clinical development leaders for oncology and rare-disease trials, and manufacturing/CMC capacity as programs advance. Day-to-day roles are Cambridge-based, not Utah-based. With $299M raised and typical oncology burn rates, the company will likely need additional capital for later-stage trials even after the 2026 Series B extension. ## Who Could Help Useful helpers include elite biotech investors (Column Group, Lux Capital, Regeneron Ventures already involved), oncology clinical investigators for AKT1-mutant and HHT trials, structural-biology collaborators, CRO partners for Phase 1/2 execution, and University of Utah technology-transfer and faculty entrepreneurs who can connect Utah trainees to Boston-area roles when the science originated locally. ## Utah Context Atavistik is not a Utah employer for most day-to-day work — headquarters and clinical operations are Cambridge-centric. The Utah connection is real but indirect: founding science from the Jared Rutter lab at the University of Utah, Rutter's continued faculty role, and the company as a proof point that deep Utah academic biochemistry can spawn platform biotech with globally selective investors. Readers evaluating meaningful work in Utah should not mistake Atavistik for a local bench job; they should understand it as a U of U success story and a signal of what the ecosystem can originate even when commercialization migrates to established biotech hubs. ## Evidence - [Official Website: Atavistik Bio](atavistik-bio-official-website.md) ## See Also - [Recursion Pharmaceuticals](recursion-pharmaceuticals.md) — another Utah-rooted life-science company with platform-scale drug-discovery ambition (different mechanism and stage). ## Open Questions - Pipeline emphasis appears to have shifted toward HHT for ATV-1601 in 2026 official communications while legacy intake centered AKT1 E17K solid tumors — what is the current status of each indication? - Allosteric drug development has high historical attrition; context-dependent binding remains a recurring failure mode. - ATV-1601 Phase 1 efficacy is unproven; data will be a major inflection point for the platform narrative. - $299M raised implies significant burn; later-stage oncology trials will likely require hundreds of millions more. - Competition includes Relay Therapeutics, Recursion (allosteric adjacency), and major pharma discovery groups. - No allosteric drug from de novo allosteric-site discovery has yet received clinical approval — platform novelty is high, clinical proof is still ahead. - The placeholder hero should be replaced with a cleared science or team image when rights are confirmed.